Serum half-life and in-vivo actions of recombinant bovine placental lactogen in the dairy cow.
The clearance rate of recombinant bovine placental lactogen (rbPL) from the blood serum of four lactating dairy cows was measured using a specific radioimmunoassay. Two animals were non-pregnant, while the other two were at approximately 120 days of gestation. The rbPL was administered as an i.v. bolus injection (4 mg total) via an indwelling jugular catheter. Blood samples were taken periodically for 180 min and assayed for rbPL. Analysis of the clearance curves for the bolus injection suggested a single-compartment model and a serum half-life of 7.25 min. In a second experiment with the same animals, following cessation of lactation, rbPL or bovine GH (bGH) were administered by s.c. injection (50 mg/day) for 5 consecutive days. Blood samples were taken twice per day during the treatment period and a 3-day pretreatment period. Samples were analysed for glucose, blood urea nitrogen (BUN), non-esterified fatty acids (NEFA), creatinine, insulin, insulin-like growth factor-I (IGF-I) and IGF-II, tri-iodothyronine (T3), progesterone and IGF-binding protein-2 (IGFBP-2) to determine whether rbPL mediates similar metabolic effects to those of bGH. Administration of bGH stimulated an increase in NEFA, glucose, T3 and insulin, whereas none of these variables was affected by rbPL. The plasma concentrations of IGF-I and IGF-II were both increased by treatment with rbPL but, to a lesser extent than occurred with bGH. Interestingly, BUN and IGFBP-2 concentrations were reduced equally by bGH and rbPL. These results suggest that rbPL does not necessarily act as a GH agonist but, rather, may have distinct effects on intermediary metabolism that could be mediated through another specific receptor.
Byatt
J C
JC
Monsanto Company, St Louis, Missouri 63198.
Eppard
P J
PJ
Veenhuizen
J J
JJ
Sorbet
R H
RH
Buonomo
F C
FC
Curran
D F
DF
Collier
R J
RJ
D000818:Animals; D002417:Cattle / Q000378:metabolism*; D005260:Female; D013006:Growth Hormone / Q000493:pharmacokinetics; D006207:Half-Life; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007335:Insulin-Like Growth Factor II / Q000032:analysis; D007774:Lactation / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D010928:Placental Lactogen / Q000097:blood / Q000493:pharmacokinetics*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000378:metabolism*; D011994:Recombinant Proteins / Q000097:blood / Q000493:pharmacokinetics*; D014284:Triiodothyronine / Q000097:blood
D011994:Recombinant Proteins; D014284:Triiodothyronine; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone; D010928:Placental Lactogen